Log in

Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from pubilc media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

CompanyDateActionBrokerageRatingPrice TargetImpact on PriceActions
BCDA
Biocardia
11/26/2019Reiterated byBrookline Capital ManagementBuyLow    
BCDA
BioCardia
11/26/2019Initiated byBrookline Capital ManagementBuy $22.00Low    
MDNA
Medicenna Therapeutics
11/19/2019Reiterated byBrookline Capital ManagementBuy C$4.00N/A    
BCEL
Atreca
8/20/2019Reiterated byBrookline Capital ManagementBuyHigh    
SCYNEXIS logo
SCYX
SCYNEXIS
8/19/2019Reiterated byBrookline Capital ManagementBuyHigh    
Vaxart logo
VXRT
Vaxart
8/15/2019Initiated byBrookline Capital ManagementBuy $6.00Low    
Celsion logo
CLSN
Celsion
7/25/2019Reiterated byBrookline Capital ManagementBuyMedium    
Chiasma logo
CHMA
Chiasma
7/24/2019Reiterated byBrookline Capital ManagementBuyLow    
Progenics Pharmaceuticals logo
PGNX
Progenics Pharmaceuticals
7/29/2019Initiated byBrookline Capital ManagementBuy $10.00Low    
Veru logo
VERU
Veru
7/29/2019Initiated byBrookline Capital ManagementBuy $12.00High    
Heat Biologics logo
HTBX
Heat Biologics
7/29/2019Initiated byBrookline Capital ManagementBuy$8.00 -> $8.00High    
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
7/29/2019Initiated byBrookline Capital ManagementBuy$6.00 -> $6.00High    
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
7/24/2019Reiterated byBrookline Capital ManagementBuyHigh    
QBIO
Q BioMed
5/10/2019Reiterated byBrookline Capital ManagementBuyLow    
Chiasma logo
CHMA
Chiasma
2/6/2019Reiterated byBrookline Capital ManagementBuyLow    
SCYNEXIS logo
SCYX
SCYNEXIS
1/4/2019Reiterated byBrookline Capital ManagementBuyHigh    
REXN
Rexahn Pharmaceuticals
11/27/2018Reiterated byBrookline Capital ManagementBuyN/A    
Celsion logo
CLSN
Celsion
11/20/2018Reiterated byBrookline Capital ManagementBuyMedium    
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
11/20/2018Reiterated byBrookline Capital ManagementBuyLow    
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
9/27/2018Reiterated byBrookline Capital ManagementBuyLow    
Heat Biologics logo
HTBX
Heat Biologics
8/1/2018Reiterated byBrookline Capital ManagementBuyLow    
Histogenics logo
HSGX
Histogenics
8/1/2018Reiterated byBrookline Capital ManagementBuyMedium    
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
7/27/2018Downgraded byBrookline Capital ManagementBuy -> HoldLow    
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
6/26/2018Reiterated byBrookline Capital ManagementBuyMedium    
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
5/1/2018Reiterated byBrookline Capital ManagementBuyLow    

This page was last refreshed on Sunday at 10:23 AM ET.

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  17,642 (Vote Outperform)
Underperform Votes:  24,451 (Vote Underperform)
Total Votes:  42,093
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recmomendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel